Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Residual cancer burden linked to long-term survival

Key clinical point: Residual cancer burden (RCB) is strongly associated with long-term survival across breast cancer subtypes.

Major finding: For triple-negative breast cancer, patients with pathologic complete response had a 10-year event-free survival among of 86%, a rate that decreased as RCB increased (RCB-I, 75%; RCB-II, 61%; RCB-III, 25%).

Study details: A meta-analysis of 5,160 patients with breast cancer treated at multiple institutions.

Disclosures: The investigators disclosed relationships with Seattle Genetics, Almac, Syndax, and others.

Citation:

Yau et al. SABCS 2019. Abstract GS5-01.